nanosymposium - Society for Neuroscience

9:00 AA29 357.10 Effects of intravenous immunoglobulin on
pathological conformations of alpha synuclein. L. M. SMITH*;
A. KLAVER; M. COFFEY; D. LOEFFLER. William Beaumont
Hosp. Res. Inst., William Beaumont Hosp. Res. Inst.
10:00 AA30 357.11 Cognitive dysfunction and cholinergic
alterations prior to DA loss in mice over-expressing wild-type
human alpha-synuclein (Thy1-aSyn mice). I. MAGEN*; K.
M. CARDIFF; D. DINH; K. DE LA ROSA; J. KWONG; E.
MASLIAH; M. CHESSELET. UCLA, UCSD.
11:00 AA31 357.12 Regionally specific microglial activation
precedes neuropathology and peripheral immune response
in mice over-expressing wildtype alpha synuclein. M. B.
WATSON*; S. K. LEE; F. RICHTER; E. MASLIAH; M.
CHESSELET. UCLA, UCLA, UCSD.
8:00 AA32 357.13 Progressive synucleinopathy in a novel,
non-genetic rat model of parkinsonism. P. J. YAROWSKY*;
K. A. MCDOWELL; W. SHEN. Univ. Maryland, Sch. of Med.,
Maryland VA Hlth. Care Syst., Univ. of Maryland.
9:00 AA33 357.14 Targeting GATA2 to transcriptionally
ameliorate alpha-synuclein and iron pathologies in
Parkinson’s disease. M. P. HOROWITZ*; J. R. CANNON;
T. J. SEW; L. M. MONTERO; Q. BAI; E. A. BURTON;
J. T. GREENAMYRE. Univ. Pittsburgh, Med. Scientist
Training Program (MSTP), Ctr. for Neurosci. Univ. of
Pittsburgh (CNUP), Dept. of Neurol., Pittsburgh Inst.
for Neurodegenerative Dis., Dept. of Neurol., Dept. of
Microbiology and Mol. Genet., PIttsburgh VA Healthcare
Syst., Med. Scientist Training Program (MSTP).
10:00 AA34 357.15 Ultrasonic vocalizations in mice
overexpressing human wild-type alpha-synuclein. J. N.
BASKEN; L. M. GRANT; F. RICHTER; K. DE LA ROSA; J.
E. MILLER*, Dr.; C. M. FOX; S. A. WHITE; E. MASLIAH;
M. CHESSELET; M. R. CIUCCI. Univ. of Wisconsin, David
Geffen Sch. of Medicine, UCLA, Integrative Biol. & Physiol.,
Natl. Ctr. for Voice and Speech, UCSD Sch. of Med., Reed
Neurolog. Res. Ctr.
11:00 AA35 357.16 The impact of transglutaminase 2
modulation on alpha-synuclein-associated phenotype in vivo.
H. GROSSO*; K. LEE; G. V. JOHNSON; R. M. GRAHAM; E.
MASLIAH; E. JUNN; M. M. MOURADIAN. UMDNJ-Robert
Wood Johnson Med. Sch., Univ. of Rochester, Victor Change
Cardiac Res. Inst., Univ. of California at San Diego.
8:00 AA36 357.17 Tissue-specific elevation of alphasynuclein
spliced transcript levels in Parkinson’s disease
brain tissues and in a transgenic mouse model of human
alpha-synuclein overexpression. J. R. MCLEAN*; P. J.
HALLETT; O. COOPER; M. STANLEY; O. ISACSON.
Harvard Med. Sch.
9:00 BB1 357.18 Biochemical investigation of alpha
synuclein accumulation in an experimental mouse model of
Parkinson’s disease. L. R. MANGIERI*. Univ. of Alabama At
Birmingham.
10:00 BB2 357.19 Brain region specific histopathological
alterations in mice overexpressing wild-type human alphasynuclein
under the Thy1 promoter. C. ZHU*; F. RICHTER;
C. HUTSON; S. SUBRAMANIAM; N. FRANICH; E.
MASLIAH; M. CHESSELET. UCLA, UCSD, UCLA.
11:00 BB3 357.20 Inhibition of prolyl oligopeptidase
disturbs its subcellular colocalization with α-synuclein and
reduces α-synuclein aggregation. T. T. MYÖHÄNEN*; M.
J. HANNULA; R. VAN ELZEN; M. GERARD; P. VAN DER
VEKEN; A. GARCIA-HORSMAN; V. BAEKELANDT; P.
T. MÄNNISTÖ; A. LAMBEIR. Univ. of Helsinki, Univ. of
Antwerp, Katholieke Univ. Leuven-Kortrijk, Univ. of Antwerp,
Katholieke Univ. Leuven.
8:00 BB4 357.21 Characterization of β-synuclein and
α-synuclein Δ70-83 expressing rAAV vectors as controls for
α-synuclein expression in vivo. N. LANDECK*; K. BUCK; D.
KIRIK. BRAINS Unit, Lund Univ.
9:00 BB5 357.22 Impact of phospholipid membranes
on alpha-synuclein self-assembly and neurotoxicity in
Parkinson’s disease. A. M. GRIGGS; K. HEAD; H. ZHANG;
L. STANCIU; J. ROCHET*. Purdue Univ., Purdue Univ.,
Purdue Univ.
10:00 BB6 357.23 Altered phosphorylation of 14-
3-3 proteins in models of Parkinson’s disease. T. A.
YACOUBIAN*; S. R. SLONE. Univ. Alabama Birmingham,
Univ. of Alabama at Birmingham.
11:00 BB7 357.24 • Direct visualization of alpha synuclein
oligomers in rat brain. H. DIMANT; L. V. KALIA; S. K.
KALIA; L. N. KIBUUKA; D. EBRAHIMI-FAKHARI; N. R.
MCFARLAND; P. J. MCLEAN*. Massgeneral Inst. For
Neurodegenerative Dis., Univ. of Florida.
8:00 BB8 357.25 • Novel structure based designed
compound reduces accumulation of toxic alpha-synuclein
and improves deficits in a transgenic murine model of
PD/DLB. D. L. PRICE*; A. D. PAULINO; T. GONZALEZ-
RUELAS; K. UBHI; E. ROCKENSTEIN; I. TSIGELNY; W.
WRASIDLO; H. MOESSLER; E. MASLIAH. Neuropore
Therapies, Inc., UC San Diego, UC San Diego, UC San
Diego.
9:00 BB9 357.26 Alpha-synuclein overexpressing
transgenic mice show peripheral organ pathology and
autonomic deficits. P. HALLETT*; J. R. MCLEAN; A.
KARTUNEN; O. ISACSON. McLean Hospital/Harvard Med.
Sc.
10:00 BB10 357.27 Effect of alpha-synuclein phosphorylation
by Polo-Like Kinase 2 on alpha-synuclein aggregation and
toxicity in vivo. O. ABID*; B. SCHNEIDER; P. AEBISCHER;
H. LASHUEL. EPFL.
POSTER
358. Huntington’s Disease: Animal Models II
Theme C: Disorders of the Nervous System
Mon. 8:00 AM – Walter E. Washington Convention
Center, Hall A-C
8:00 BB11 358.01 Efficacy of a novel proneurogenic
neuroprotective small molecule, P7C3, in the R6/2
transgenic mouse model of Huntington’s disease. G. L.
BECKER*; M. TANG; S. HUSAIN; C. P. PHILIP; P. J.
HUNTINGTON; A. R. BURKET; S. L. MCKNIGHT; A. A.
PIEPER. Univ. of Texas Southwestern Med. Sch., Univ. of
Texas Southwestern Med. Sch.
9:00 BB12 358.02 Serine 421 is a crucial mediator of
pathology in a mouse model of Huntington’s disease. I.
H. KRATTER*; H. ZAHED KARGARAN; A. ZANDONA;
A. S. TSVETKOV; X. GU; X. W. YANG; E. MASLIAH; S.
FINKBEINER. Gladstone Inst. For Neurolog. Dis., UCSF,
Taube-Koret Ctr. for Huntington’s Dis. Res., UCLA, UCSD,
UCSF.
10:00 BB13 358.03 Selective decrease in the function of
postsynaptic striatal A2A receptors in presymptomatic
stages of a rat model of Huntington’s disease. M. ORRU’; J.
ZANOVELI; X. GUITART*; C. QUIROZ; V. BEAUMONT; S.
FERRE’. NIDA/IRP/DHHS/NIH, UFPR, NIMH / NIH, CHDI
Fndn.
34 | Society for Neuroscience • Indicated a real or perceived conflict of interest, see page 162 for details.
� Indicates a high school or undergraduate student presenter.